Oslo, June 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, announces revised terms of the employee share option program. Ultimovacs has during the second quarter of this year implemented a cash preservation program that includes downsizing of the organization. As a measure to stimulate retention of non-redundant team members, the board of directors of Ultimovacs ASA has decided to revise the terms of parts of the share option program. The terms of the already...
The post Ultimovacs ASA announces revised terms of the employee share option program appeared first on Vietnam Insider.